Drugs / XMT-2056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05514717 | Jan 2023 → May 2026 | HER2 positive breast carcinoma, non-small cell lung carcinoma | Day One Biopharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XMT-2056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05514717 ↗ |
| Route | Intravenous | “administered through a vein in your arm or port catheter (intravenously)” NCT05514717 ↗ |